Palisades Investment Partners LLC Increases Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Palisades Investment Partners LLC grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 400,663 shares of the biotechnology company's stock after acquiring an additional 51,658 shares during the period. ADMA Biologics comprises 2.9% of Palisades Investment Partners LLC's holdings, making the stock its 12th biggest position. Palisades Investment Partners LLC owned about 0.17% of ADMA Biologics worth $6,871,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its stake in shares of ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after purchasing an additional 700 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of ADMA Biologics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after purchasing an additional 746 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock valued at $614,000 after purchasing an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System lifted its stake in shares of ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after purchasing an additional 897 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 7,779 shares of the company's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the completion of the transaction, the director now directly owns 114,830 shares in the company, valued at approximately $2,333,345.60. This represents a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ADMA has been the subject of several analyst reports. Wall Street Zen cut shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $24.25.

ADMA Biologics Price Performance

NASDAQ:ADMA traded up $0.26 during trading hours on Friday, reaching $20.42. 1,316,575 shares of the company were exchanged, compared to its average volume of 3,702,325. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock's 50-day moving average is $20.67 and its 200-day moving average is $18.91. The firm has a market cap of $4.87 billion, a PE ratio of 72.93 and a beta of 0.57. ADMA Biologics, Inc. has a twelve month low of $9.35 and a twelve month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business's revenue was up 40.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 earnings per share. On average, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.